Linagliptin/metformin HCl (fixed combination therapy) for the treatment of Type 2 diabetes mellitus

References

• Hajat C, Harrison O, Shather Z. A profile and approach to chronic disease in Abu Dhabi. Global Health 2012;8:18
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation. 2013. Available from: www.idf.org/diabetesatlas
   Google Scholar
• Kim W, Egan JE. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60(4):470-512
   PubMed Web of Science ®Google Scholar
• Moore B. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J 1906;1:28-38
   PubMedGoogle Scholar
• Sarson DL. Gastric inhibitory polypeptide (GIP). J Clin Pathol Suppl 1978;8:31-7
   Google Scholar
• Ahren B. The dynamic incretin adaptation and type 2 diabetes. J Clin Endocrinol Metab 2011;96:620-2
   PubMed Web of Science ®Google Scholar
• Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967;46(12):1954-62
   PubMed Web of Science ®Google Scholar
• Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985;28(9):704-7
   PubMed Web of Science ®Google Scholar
• Dungan K, Buse JB. Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide. Clin Diabetes 2005;23:56-62
   Google Scholar
• Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Therap 2007;113(3):546-93
   PubMed Web of Science ®Google Scholar
• Holz GG, Kühtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993;361(6410):362-5
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359(9309):824-30
   PubMed Web of Science ®Google Scholar
• Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60(11):1454-70
   PubMed Web of Science ®Google Scholar
• Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008;34(suppl 2):S65-72
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes. Diabetes Metab Syndr Obes 2013;6:1-9
   PubMedGoogle Scholar
• Yki-Järvinen H, Rosenstock J, Durán-Garcia S, et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study. Diabetes Care 2013;36(12):3875-81
   PubMed Web of Science ®Google Scholar
• Vigneri R, Goldfine ID. Role of metformin in treatment of diabetes mellitus. Diabetes Care 1987;10(1):118-22
   PubMed Web of Science ®Google Scholar
• Papanas N, Maltezos E. Metformin: a review of its use in the treatment of type 2 diabetes. Clin Med Therap 2009;1:1367-81
   Google Scholar
• Frei A, Herzog S, Woitzek K, et al. Characteristics of poorly controlled type 2 diabetes patients in Swiss primary care. Cardiovasc Diabetol 2012;11:70
   PubMed Web of Science ®Google Scholar
• Rottlaender D, Scherner M, Schneider T, et al. Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany. Dtsch Med Wochenschr 2007;132(4):139-44
   PubMed Web of Science ®Google Scholar
• Leichter SB, Thomas S. Combination medications in diabetes care: an opportunity that merits more attention. Clin Diabetes 2003;21:175-8
   Google Scholar
• Jentadueto ^® [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc: Ridgefield, CT; 2014
   Google Scholar
• European Medicines Agency (2015, January 22). Jentadueto. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002279/human_med_001574.jsp&mid=WC0b01ac058001d124 [Last accessed 27 January 2015]
   Google Scholar
• Scheen AJ. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. Expert Opin Drug Metab Toxicol 2013;9(3):363-77
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report. Jentadueto: linagliptin/metformin hydrochloride. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002279/WC500130972.pdf [Last accessed 08 February 2015]
   Google Scholar
• Scheen AJ. Efficacy and safety of Jentadueto® (linagliptin plus metformin). Expert Opin Drug Saf 2013;12(2):275-89
   PubMed Web of Science ®Google Scholar
• Johansen OE, Neubacher D, Seck T, et al. Cardiovascular (CV) safety of linagliptin in patients with type 2 diabetes: a pooled comprehensive analysis of prospectively adjudicated CV events in phase 3 studies. 49th Ann Mtg of the European Association for the Study of Diabetes (EASD), Barcelona, 23-27 Sep 2013
   Google Scholar
• Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013;10(4):289-301
   PubMed Web of Science ®Google Scholar
• Inagaki N, et al. Efficacy and tolerability of linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, in people with Type 2 Diabetes mellitus (T2DM) and liver disease: A pooled analysis of 17 randomised placebo-controlled double-blind studies Oral presentation at the 2013 International Conference on Diabetes and Metabolism & 5th Asian Association for the Study of Diabetes, Seoul, Korea; 6-9 November 2013; Seoul, Korea [Abstract NO.ICDM2013-192]
   Google Scholar
• Kim SH, et al. Efficacy and safety of Linagliptin in T2DM patients with chronic liver disorder. Joint 10th Congress of International Diabetes federation Western Pacific Region (IDF - WPR), 6th scientific meeting of the Asian association of study of diabetes (AASD), Singapore; 21-24 Nov 2014
   Google Scholar